Ansell Limited has delivered adjusted earnings per share of US148.6ยข for the full year ended 30 June 2026, landing in the upper half of the company’s guidance range. This represents growth of 17.8% on an organic constant currency basis from the prior year’s US126.1ยข, demonstrating the company’s ability to drive earnings expansion through higher sales volumes and operational improvements despite challenging macro conditions including US tariff pressures and elevated costs from Middle East geopolitical tensions.
Sales revenue reached US$2,140.2m, a 5.0% increase on an organic constant currency basis, with growth accelerating through the second half of the financial year. On an adjusted basis excluding temporary order pattern benefits, the underlying sales growth was 5.7%. More importantly, the company achieved significant margin expansion with adjusted EBIT margin expanding 140 basis points to 15.0%, driven by a combination of higher sales volumes in premium product segments, increased synergies from prior acquisitions, and enhanced supply chain productivity. Adjusted EBIT grew 14.9% to US$321.9m, outpacing sales growth and highlighting the operating leverage in the business.
The company’s cash generation remained robust, with operating cash flow of US$270.1m representing 113% cash conversion of earnings. This strong cash position has enabled Ansell to continue its shareholder returns through both dividends and share buybacks. The full year dividend per share of US68.1ยข was set at a 45% payout ratio, consistent with the company’s stated policy, while the buyback program progressed with US$118.4m of the existing US$200m authorization completed in FY26. The company has confirmed it will continue the buyback program into FY27, signaling confidence in its valuation and capital structure.
Performance across key markets underscores the success of Ansell’s strategic focus. Cleanroom sales grew 10% on an adjusted basis, reflecting strong demand in the scientific vertical and supporting the company’s positioning in higher-margin segments. Similarly, US market sales grew 10%, demonstrating traction in a core geographic market. These results suggest the company’s product mix shift toward premium offerings is gaining momentum, with pricing actions successfully offsetting inflationary pressures from global supply chain disruptions.
The combination of volume growth acceleration, margin expansion, and resilience through global headwinds positions Ansell well for continued performance. Investors should monitor the trajectory of sales growth in coming periods, particularly whether the second half acceleration can be sustained, and track the ongoing impact of tariff policies on sourcing economics. The company’s ability to continue margin expansion while absorbing macro uncertainties will be critical to delivering on investor expectations. This announcement is price sensitive and has been flagged as material by the ASX.
View the full ASX announcement (PDF)
About Ansell Limited (ASX: ANN)
Ansell Limited is a global manufacturer of protective equipment, specializing in gloves and bodywear for healthcare and industrial applications. The company generates approximately 55 percent of revenue from healthcare markets where it supplies surgical gloves, examination gloves, and protective garments to hospitals and medical facilities. Its industrial division serves automotive, chemical, construction, mining, and other sectors across major markets in North America, Europe, Asia-Pacific, and Latin America.
If you would like to discuss this announcement or how it might affect your portfolio, request a callback or call us on 1300 889 603.
